BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio
November 14, 2022 08:30 ET
|
BrightInsight
SAN JOSE, Calif. and LAS VEGAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, today at...
Axtria Leads Discussion on Pharma’s Advanced Uses of Data Analytics and Artificial Intelligence With 6 Sessions at PMSA 2021 Annual Conference
June 16, 2021 08:00 ET
|
Axtria Inc.
Berkeley Heights, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- With the elevated importance of data analytics and artificial intelligence (AI)-driven intelligence technology systems for a global life...
uniQure announces closing of commercialization and license agreement with CSL Behring
May 06, 2021 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
June 24, 2020 16:05 ET
|
uniQure Inc.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...
BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases
May 06, 2020 08:30 ET
|
BrightInsight; CSL Behring
SAN JOSE, Calif. and KING OF PRUSSIA, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- BrightInsight, Inc., the provider of the leading regulated IoT platform for biopharma and medtech, and CSL Behring, a...